Skip to content
The Policy VaultThe Policy Vault

Lynparza (olaparib) — Medica

Breast cancer – adjuvant therapy

Initial criteria

  • age ≥ 18 years
  • germline BRCA mutation-positive breast cancer
  • HER2-negative breast cancer
  • has tried neoadjuvant or adjuvant therapy

Approval duration

1 year (total)